News
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors
SAN DIEGO, Calif. – August 27, 2026 – Ambros Therapeutics, Inc., today announced the appointments of John C. Jacobs and Scott Robertson to its Board of Directors. Mr. Jacobs is a seasoned industry leader with more than 25 years of commercial, operations, business and leadership experience and currently serves as President, Chief Executive Officer and member of the board of directors of Novavax, Inc. Mr. Robertson has over 20 years of life sciences operating, investing and investment banking experience and currently serves as Chief Business Officer and Chief Financial Officer of Star Therapeutics, Inc.
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
WALTHAM, Mass. and SAN DIEGO, Calif. – August 21, 2026 – Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
IRVINE, Calif. – June 11, 2026 – Ambros Therapeutics, Inc., today announced the appointment of Cris Calsada as Chief Financial Officer (CFO) and Claire Padgett, Ph.D., as Senior Vice President (SVP) of Clinical Operations and Program Management. Ms. Calsada will oversee the company’s finance organization, including financial strategy, capital planning, and investor relations. Dr. Padgett will oversee clinical operations and program management, including the pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1).
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
IRVINE, Calif. – June 8, 2026 – Ambros Therapeutics, Inc. today announced that the first patient has been dosed in its pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate versus placebo for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1). CRPS-1 is a severe, debilitating rare disease with an estimated 65,000 new cases annually in the United States.
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
IRVINE, Calif. -- March 31, 2026 -- Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new U.S. patent application covering methods of selectively treating patients having Complex Regional Pain Syndrome Type 1 (CRPS-1), an orphan designated disease.  The granting of this patent will enhance the Company’s intellectual property (IP) portfolio and strengthen the potential for neridronate exclusivity through 2045.
Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1
IRVINE, Calif. -- December 16, 2025 -- Ambros Therapeutics, Inc. today announced its launch as a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases beginning with neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). Ambros launches with an oversubscribed $125 million Series A financing co-led by RA Capital Management and Patient Square Capital's platform Enavate Sciences, joined by Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners LP, and other dedicated life sciences investors.

Loading...